Pharming Group

Save the date 📅 On July 30, 2026, we'll report our second quarter and first half year 2026 financial results and provide a business update. Our management team looks forward to sharing the results and discussing recent progress at 13:30 CEST / 07:30 EDT. 🔗 For more information and to register: https://lnkd.in/emJaiaDC

From June 22–25, our team Björn Peters Jonathon Fendelman Kalpana Ramakrishnan will be in San Diego for the BIO International Convention, connecting with partners, peers and innovators across the global biotech community. This year’s BIO theme, Driven by Purpose, feels especially relevant in rare diseases, where progress depends on shared commitment, focused science and the right partnerships. For us, collaboration isn’t a step in the process. It is the process — helping bring together the expertise, experience and purpose needed to address some of the toughest rare disease challenges. Interested in partnering with us? Learn more here: https://lnkd.in/egqZpPUe See you in San Diego! #BIO2026

Listening is not optional in rare disease innovation and care. Behind every diagnosis is more than most people see: unanswered questions, missed signals, and too often, time patients and families cannot afford to lose. In his article for The Medicine Maker, our CEO Fabrice Chouraqui explores why patient voices must form the basis of rare disease innovation, from diagnosis and clinical development to access and policy. At Pharming, we believe progress matters only when it reaches patients – and that starts by listening to the people living the journey every day. Read the full article here: https://lnkd.in/edPsN6PC

What does tax leadership look like in a more fragmented world? Last week, our Director Tax, Verena Soignon, attended the EY Tax Leadership Summit as a panelist, joining around 200 tax, finance and business leaders to explore that question. The discussion reflected on the realities facing tax teams today: shifting geopolitics, rapid technological change, evolving global tax rules, greater regulatory scrutiny and rising expectations from stakeholders. For Pharming, conversations like these matter. Responsible leadership across every function helps us stay focused, resilient and ready to deliver long-term value as we continue working to serve people living with rare diseases. Thank you to EY for bringing people together to discuss these important topics, and to moderator Laura Mair, and fellow panel members Jennifer Korpinen, Alistair Collins and Joana Dermendjieva, for an engaging discussion.

In rare disease, progress isn’t defined by a single moment. It's built over time.     The experiences of patients, families and colleagues help keep our work anchored in what matters most.    They remind us why listening matters, why innovation must be purposeful, and why continued progress is critical for people who often have nowhere else to turn.    Hear the stories that continue to shape our work: https://lnkd.in/eT-KQ2DT

Progress in rare disease depends on more than ambition.    It requires disciplined execution, strong standards, and a clear sense of responsibility at every step.    At Pharming, that mindset underpins how we work—and how we aim to deliver lasting impact over time.    Learn more about our commitment and how the Pharming mindset creates the foundation for meaningful impact: https://lnkd.in/e95Nr8iA  

Listening is part of the work. In rare disease, progress is stronger when it reflects real experiences of patients, families, caregivers and the wider community. Those perspectives help keep our work grounded, relevant and connected to what matters most. Learn more about how listening informs our approach: https://lnkd.in/ekwfwBXX

Science only matters if it leads to real understanding. That’s what drives our work in rare disease. At Pharming, we focus our efforts where the need is clear—always guided by the lived experiences of patients, informed by science, and grounded in the realities patients face. Learn more about how we are advancing rare disease care: https://lnkd.in/evBXVx6T

Behind every step forward is a team making deliberate choices—guided by science, shaped by patient experience, and grounded in collaboration.    Progress depends on people with unique expertise working together for a shared purpose: improving outcomes for those living with rare diseases.    Meet some of the people behind that work. https://lnkd.in/eTvW93Qz

🎤Our Chief Executive Officer, Fabrice Chouraqui, will participate in a Fireside Chat at the 2026 Jefferies Global Healthcare Conference on Thursday June 4, 2026 at 11:05am EDT/17:05 CEST.   Attending the conference? Please reach out 📩 www.pharming.com/our-news